Introduction
Can broad-spectrum vitamin and mineral supplements improve anxiety, depression or emotional regulation?
In this Premium-exclusive episode, we examine three randomised, placebo-controlled trials from Professor Julia Rucklidge’s research group: NoMAD, investigating anxiety and depressive symptoms in adults; NUTRIMUM, examining depressive symptoms during pregnancy; and BEAM, studying irritability and emotional dysregulation in adolescents.
These studies offer an opportunity to explore some central challenges in interpreting nutrition and mental health research. What does “faster improvement” mean when groups reach similar outcomes by the end of a trial? How should improvements in overall functioning be weighed against results from depression-specific measures? And how much confidence should we place in a large treatment effect found within a small subgroup?
- [02:01] Pitfalls in nutrition mental health research
- [08:57] Trial lineup and what to watch for
- [09:42] NOMAD trial design and measures
- [16:48] NOMAD results placebo vs micronutrients
- [29:23] NutriMum trial design in pregnancy
- [35:25] NutriMum results clinician vs self report
- [41:16] BEAM trial design in adolescents
- [47:25] BEAM results and DMDD subgroup signal
- [54:32] Key takeaways
Episode Resources
- Join the Sigma newsletter for free
- Subscribe to Sigma Nutrition Premium
- Enroll in the next cohort of our Applied Nutrition Literacy course
- Studies discussed:
- Related episodes:
About the Hosts
Alan Flanagan, PhD is a Postdoctoral Research Fellow at the University of Surrey, UK, where he previously completed a PhD in nutrition and a master’s degree in Nutritional Medicine. Dr. Flanagan is the founder of Alinea Nutrition, an online education hub dedicated to providing impartial, science-based nutrition reviews and analysis.
He has published in fields such as chrononutrition and research methods in nutrition (see publications).
Dr. Flanagan is a regular co-host of the podcast, as part of his role as Research Communication Officer at Sigma Nutrition.
Danny Lennon is the founder of Sigma Nutrition and host of the popular podcast Sigma Nutrition Radio since 2014. Danny has a master’s degree (MSc.) in Nutritional Sciences from University College Cork, in addition to a BSc. Degree in Biology and Physics.
He is the co-creator of the course Applied Nutrition Literacy with Dr. Alan Flanagan.
And he is currently a member of the Advisory Board of the Sports Nutrition Association, the global regulatory body responsible for the standardisation of best practice in the sports nutrition profession.
This episode examines three placebo-controlled trials of broad-spectrum vitamin and mineral formulations from Julia Rucklidge’s research group. The central question is whether supplementation improves mental health outcomes beyond the changes seen with matched monitoring and placebo. The trials involve distinct populations: community-dwelling adults with anxiety and depressive symptoms, pregnant women with depressive symptoms, and adolescents with irritability.
Overall interpretation: The adult trials did not show a clear advantage on their main depression-specific outcomes in the initial models, although there were differences in symptom trajectories or global improvement. The adolescent trial found modest benefits on two of three primary outcomes, with a larger exploratory signal in participants classified as having disruptive mood dysregulation disorder (DMDD). These findings warrant precise, population-specific conclusions.
Useful Terminology
- Broad-spectrum micronutrient intervention: A formulation supplying multiple vitamins and minerals. These trials tested particular multi-ingredient products and doses; their results cannot establish that any single nutrient, or a standard multivitamin, produces the same effects.
- Symptom score versus diagnosis: A questionnaire can quantify symptoms and identify people who need assessment. Crossing a screening threshold does not, by itself, establish a psychiatric diagnosis.
- Construct validity: Whether an instrument adequately measures the concept of interest. Depression severity, irritability, emotional reactivity and overall functioning are related but distinct constructs.
- Convergent validity and reliability: Convergent validity concerns agreement with measures of related constructs. Reliability concerns consistency, including agreement between raters and consistency among items. Neither guarantees that an observed change is clinically important.
- Group-by-time interaction: A test of whether the pattern or rate of change differs between treatment groups. It answers a different question from an end-of-trial comparison.
- Clinically meaningful change: Improvement large enough to matter under a specified criterion. A change threshold, remission threshold and responder definition are not interchangeable, and their values depend on the instrument and context.
- Cohen’s d: A standardised effect size. Values around 0.3–0.4 are conventionally described as small to modest, but clinical importance also depends on the outcome, precision, baseline severity and treatment burden.
- Exploratory subgroup analysis: An analysis investigating whether treatment effects differ within a subset of participants. Especially when not prespecified, it is better suited to generating hypotheses than establishing a treatment indication.
How to Evaluate These Trials
1. Identify the population and the target outcome
- Severity matters. An intervention tested in people reporting symptoms in the community does not automatically establish efficacy in major depressive disorder, a specific anxiety disorder or a more severely impaired clinical population.
- Different populations require separate conclusions. Antenatal depressive symptoms and adolescent irritability are not interchangeable with adult depression. Differences